From Low- to High-Throughput Analysis

Abstract

The high throughput is routinely used for the first steps of drug development such as drug discovery screening and toxicity. However, for PK analysis of regulated studies, the requirements and difficulties to achieve high-throughput analysis are more demanding due to regulatory guidelines that are not needed for early steps of drug discovery. High-throughput analysis can be required for any drug type from small molecules to larger ones. Contract research organizations must be prepared to deliver the results associated to these studies in a fast turnaround. Herein, we will describe the challenges encountered by a laboratory in order to go from low- to high-throughput analysis.

A Convergent Functional Genomics Analysis to Identify Biological Regulators Mediating Effects of Creatine Supplementation

“…Combined together, we enhance our ability to distinguish signals from noise, even with limited cohorts and datasets [ 46 ]; therefore, CFG is useful for identifying novel candidate genes and pathways for specific phenotypes [ 47 , 48 , 49 , 50 ] and compound-mediated gene regulation [ 51 , 52 ]. It is necessary to point out the complementary features of low- and high-throughput analysis, given that subsequent validation of the identified metabolic hubs requires the high sensitivity, lower noise, and reproducibility of low-throughput techniques (e.g., post-transcriptional regulation assessment, targeted-molecules expression, protein–protein interactions) [ 53 ].…”